Somatotropin Deficiency Market

Market Overview:

The 7 major somatotropin deficiency markets are expected to exhibit a CAGR of 3.99% during 2024-2034.

The somatotropin deficiency market has been comprehensively analyzed in IMARC's new report titled "Somatotropin Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Somatotropin deficiency refers to a medical condition characterized by insufficient production or secretion of growth hormone by the pituitary gland. This hormone is responsible for stimulating physical development and growth as well as regulating several metabolic processes. In children, somatotropin deficiency can lead to growth retardation, resulting in shorter stature compared to their peers. Various other common signs and symptoms of the illness in children include delayed puberty, decreased muscle mass, increased body fat, slow tooth development, etc. Adults suffering from this ailment might experience reduced energy levels and strength, enhanced fat around the waist, impaired memory and concentration, changes in lipid profiles, etc. The diagnosis of somatotropin deficiency involves medical history evaluation, physical examination, and specific laboratory tests to measure growth hormone levels. A healthcare provider may also perform magnetic resonance imaging (MRI) of the brain to visualize the structure of the pituitary gland and rule out any other abnormalities, such as tumors or malformations, that may affect the production of hormones. In some cases, genetic testing will be recommended to identify specific gene mutations associated with this disease.

The increasing cases of tumors or injuries in the pituitary gland or the hypothalamus, which can damage the tissues or disrupt their normal functioning, are primarily driving the somatotropin deficiency market. In addition to this, the rising incidences of genetic mutations that can affect the production, secretion, or processing of the growth hormone are also creating a positive outlook for the market. Moreover, the inflating demand for subcutaneous injections of recombinant human growth hormone (rhGH), owing to their various benefits, like convenient administration, stable absorption, improved compliance, etc., is further bolstering the market growth. Apart from this, the widespread adoption of high-intensity interval training programs, since they stimulate the release of GH in patients, thereby promoting muscle strength, tissue repair, and metabolism, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine techniques, which aim to heal damaged or dysfunctional cells to potentially enhance overall body growth in individuals suffering from the disease, is expected to drive the somatotropin deficiency market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the somatotropin deficiency market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for somatotropin deficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the somatotropin deficiency market in any manner.

Recent Developments:

• In March 2024, Lumos Pharma, Inc. obtained a Notice of Allowance from the United States Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700, titled "Compactable Oral Formulations of Ibutamoren." This patent comprises claims related to specific enhanced formulations of LUM-201 that the company expects to use in its Phase 3 study and eventually commercialize.
• In December 2023, Ascendis Pharma A/S reported positive topline results from foresiGHt, its Phase 3 randomized, placebo-controlled (double-masked), parallel-arm, and active-controlled (open-label) trial to compare the safety and efficacy of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adult people with growth hormone deficiency.
• In June 2023, Pfizer Inc. and OPKO Health Inc. announced that the U.S. FDA had approved NGENLA (somatrogon-ghla), a once in a week, human growth hormone analog designed for treating pediatric patients aged three years and up with growth failure owing to insufficient secretion of endogenous growth hormone.

Key Highlights:

• The prevalence of somatotropin deficiency is predicted to be between 1 in 4000 and 1 in 10,000.
• Each year, around 6,000 adults in the United States are diagnosed with growth hormone insufficiency.
• Adult GH insufficiency is predicted to impact one in every 100,000 persons each year, while childhood-onset GH-deficient patients have a frequency of about two instances per 100,000 people.
• Approximately 15-20% of cases represent the transition from childhood GH insufficiency to adulthood.

Drugs:

Humatrope refers to a man-made version of human growth hormone. It is used to treat children who are slow to grow because of a lack of growth hormone production. Humatrope is available in 6, 12, and 24mg cartridges for use with the HumatroPen injectable device.

Macimorelin, also known as Macrilen, is a medication created by Aeterna Zentaris for the diagnosis of adult growth hormone deficiencies. The salt formulation, Macimorelin acetate, is a synthetic growth hormone secretagogue receptor agonist. It is an agonist of the growth hormone secretagogue receptor (ghrelin receptor), which causes the pituitary gland to produce growth hormone.

LUM-201 is an orally administered small chemical that stimulates the pituitary gland to formulate growth hormone. It functions as an agonist of the growth hormone secretagogue receptor, stimulating growth hormone release.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the somatotropin deficiency market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the somatotropin deficiency market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current somatotropin deficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the somatotropin deficiency market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the somatotropin deficiency market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the somatotropin deficiency market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of somatotropin deficiency across the seven major markets?
• What is the number of prevalent cases (2018-2034) of somatotropin deficiency by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of somatotropin deficiency by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with somatotropin deficiency across the seven major markets?
• What is the size of the somatotropin deficiency patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of somatotropin deficiency?
• What will be the growth rate of patients across the seven major markets?
   

Somatotropin Deficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for somatotropin deficiency drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the somatotropin deficiency market?
• What are the key regulatory events related to the somatotropin deficiency market?
• What is the structure of clinical trial landscape by status related to the somatotropin deficiency market?
• What is the structure of clinical trial landscape by phase related to the somatotropin deficiency market?
• What is the structure of clinical trial landscape by route of administration related to the somatotropin deficiency market?